Adding pertuzumab to trastuzumab and paclitaxel in first-line treatment for patients with unresectable and/or metastatic HER2-positive BC significantly increased progression-free survival (PFS) and OS, as demonstrated by the CLEOPATRA phase III trial [49,50]. This evidence concerns the gene ERBB2 and breast cancer.